184 related articles for article (PubMed ID: 7184438)
21. Mechanisms of antitumor action of Corynebacterium parvum: replicating short-lived T cells as the mediators of potentiated tumor-specific immunity.
Tuttle RL; North RJ
J Reticuloendothel Soc; 1976 Sep; 20(3):209-16. PubMed ID: 1086362
[No Abstract] [Full Text] [Related]
22. Contrasting effects of activated and nonactivated macrophages and macrophages from tumor-bearing mice on tumor growth in vivo.
Gabizon A; Leibovich SJ; Goldman R
J Natl Cancer Inst; 1980 Nov; 65(5):913-20. PubMed ID: 6933261
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of resistance to Listeria monocytogenes enhanced by Corynebacterium parvum in mice.
Miyata H; Nomoto K; Takeya K
Immunology; 1980 May; 40(1):33-9. PubMed ID: 6968291
[TBL] [Abstract][Full Text] [Related]
24. Macrophage functions in beige (Chédiak-Higashi syndrome) mice.
Mahoney KH; Morse SS; Morahan PS
Cancer Res; 1980 Nov; 40(11):3934-9. PubMed ID: 7471044
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of the antitumor-activity of Corynebacterium parvum by appropriate adjustment of dosage schedules.
Megirian R; Astry CL; Spoor RP; Loose L
Cancer Treat Rep; 1980; 64(8-9):915-20. PubMed ID: 7448829
[TBL] [Abstract][Full Text] [Related]
26. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.
Chen L; McGowan P; Ashe S; Johnston JV; Hellström I; Hellström KE
Cancer Res; 1994 Oct; 54(20):5420-3. PubMed ID: 7522958
[TBL] [Abstract][Full Text] [Related]
27. Correlation of antitumor chemoimmunotherapy with serum inhibition of tumor cell destruction.
Fisher B; Hanlon J; Gebhardt M; Linta J; Saffer E
Cancer Res; 1978 Jan; 38(1):38-41. PubMed ID: 618581
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of antitumor action of Corynebacterium parvum: the generation of cell-mediated tumor specific immunity.
Tuttle RL; North RJ
J Reticuloendothel Soc; 1976 Sep; 20(3):197-208. PubMed ID: 978659
[No Abstract] [Full Text] [Related]
29. [Antitumor effect of bacterial lipopolysaccharide (LPS) and a combination use of LPS and lentinan on C3H/He mice bearing MH-134 tumor].
Moriya N; Miwa H; Taketsuka S; Orita K
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1646-52. PubMed ID: 6870308
[TBL] [Abstract][Full Text] [Related]
30. Enhancement by Corynebacterium parvum of the normal and tumor tissue response to hyperthermia.
Urano M; Overgaard M; Suit H; Dunn P; Sedlacek R
Cancer Res; 1978 Mar; 38(3):862-4. PubMed ID: 626985
[TBL] [Abstract][Full Text] [Related]
31. [Effect of Corynebacterium parvum on the immune response in guinea pigs. I. Mode of enhancement of the anamnestic response and development of delayted hypersensitivity after treatment with Corynebacterium parvum].
Halpern B; Gauthier-Rahman S; Besluau D
C R Seances Soc Biol Fil; 1977; 171(6):1202-8. PubMed ID: 148948
[TBL] [Abstract][Full Text] [Related]
32. Effect of Corynebacterium parvum on cytotoxicity of regional and nonregional lymph node cells from animals with tumors present or removed.
Fisher B; Wolmark N; Coyle J
J Natl Cancer Inst; 1974 Dec; 53(6):1793-801. PubMed ID: 4471644
[No Abstract] [Full Text] [Related]
33. Potentiation of antitumor immunity in tumor-bearing mice by a degraded D-manno-D-glucan (DMG), a new antitumor polysaccharide.
Nakajima H; Kita Y; Hashimoto S; Tsukada W; Abe S; Mizuno D
Jpn J Exp Med; 1983 Dec; 53(6):281-8. PubMed ID: 6680757
[TBL] [Abstract][Full Text] [Related]
34. The effect of nonspecific immune stimulation with Corynebacterium parvum and polidin on the Ehrlich ascites tumor growth.
Todoruţiu C; Rişcă R; Daicoviciu D; Mulea R
Morphol Embryol (Bucur); 1982; 28(1):77-83. PubMed ID: 6461826
[TBL] [Abstract][Full Text] [Related]
35. Development of cell-mediated antiviral immunity and macrophage activation in C3H/HeN mice infected with mouse mammary tumor virus.
Tagliabue A; Boraschi D; McCoy JL
J Immunol; 1980 May; 124(5):2203-8. PubMed ID: 6245137
[No Abstract] [Full Text] [Related]
36. Effects of neoplasms on inflammation: depression of macrophage accumulation after tumor implantation.
Snyderman R; Pike MC; Blaylock BL; Weinstein P
J Immunol; 1976 Mar; 116(3):585-9. PubMed ID: 176265
[TBL] [Abstract][Full Text] [Related]
37. Dibutyryl cyclic AMP protects Corynebacterium parvum-treated mice against lipopolysaccharide-induced lethal toxicity.
Inoue H; Takahashi S; Nomoto K; Yoshikai Y
Cell Immunol; 1995 Apr; 162(1):1-7. PubMed ID: 7704897
[TBL] [Abstract][Full Text] [Related]
38. Antitumor immunity induced by hybrid murine tumor cells: requirements for optimal immunization.
McCune CS; O'Donnell RW; Horan PK; Budd HS; Spennacchio JL; Chuang C; Henshaw EC
J Natl Cancer Inst; 1982 Sep; 69(3):647-52. PubMed ID: 6955557
[TBL] [Abstract][Full Text] [Related]
39. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. X. Effect of treatment on tumor cell kinetics in mice.
Fisher B; Gunduz N
J Natl Cancer Inst; 1979 Jun; 62(6):1545-51. PubMed ID: 286125
[No Abstract] [Full Text] [Related]
40. Treatment of C3H mice bearing solid Gardner lymphosarcoma with vaccine prepared from Corynebacterium parvum combined with methotrexate and Alexan.
Motycka K; Chudomel V; Bednár M; Bostík J
Arch Immunol Ther Exp (Warsz); 1984; 32(4):413-9. PubMed ID: 6549500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
